136 related articles for article (PubMed ID: 527209)
1. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
Monjanel S; Rigault JP; Cano JP; Carcassonne Y; Favre R
Cancer Chemother Pharmacol; 1979; 3(3):189-96. PubMed ID: 527209
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.
Lena N; Imbert AM; Pignon T; Favre R; Meyer G; Cano JP; Carcassonne Y
Cancer Chemother Pharmacol; 1984; 12(2):120-4. PubMed ID: 6697425
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.
Luyckx M; Cazin JL; Brunet C; Gosselin P; Demaille MC
Eur J Clin Pharmacol; 1985; 28(4):457-62. PubMed ID: 3839754
[TBL] [Abstract][Full Text] [Related]
4. High-dose oral methotrexate.
McVie JG; Stuart JF; Calman KC; Reid JL
Cancer Treat Rep; 1981; 65 Suppl 1():141-3. PubMed ID: 7198935
[TBL] [Abstract][Full Text] [Related]
5. Bayesian estimation and prediction of clearance in high-dose methotrexate infusions.
Iliadis A; Bachir-Raho M; Bruno R; Favre R
J Pharmacokinet Biopharm; 1985 Feb; 13(1):101-15. PubMed ID: 3839529
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate test-dose protocol in the presence of 7-hydroxy-methotrexate.
Lena N; Imbert AM; Favre R; Cano JP; Carcassonne Y
Eur J Cancer Clin Oncol; 1987 May; 23(5):481-5. PubMed ID: 3477455
[TBL] [Abstract][Full Text] [Related]
7. Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol.
Cano JP; Bruno R; Lena N; Favre R; Iliadis A; Imbert AM
Cancer Drug Deliv; 1985; 2(4):271-6. PubMed ID: 3864520
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
Lokich JJ; Curt G
Cancer; 1985 Nov; 56(10):2391-4. PubMed ID: 4042071
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate-vindesine association in head and neck cancer: modification of methotrexate's hydroxylation in presence of vindesine.
Bore P; Lena N; Imbert AM; Favre R; Cano JP; Meyer G; Carcassonne Y
Cancer Chemother Pharmacol; 1986; 17(2):171-6. PubMed ID: 3719898
[TBL] [Abstract][Full Text] [Related]
10. The protein binding and elimination of methotrexate after intravenous infusions in cancer patients.
Paxton JW
Clin Exp Pharmacol Physiol; 1982; 9(3):225-34. PubMed ID: 7140004
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.
Iven H; Brasch H; Engster J
Cancer Chemother Pharmacol; 1985; 15(2):115-20. PubMed ID: 4017160
[TBL] [Abstract][Full Text] [Related]
13. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
14. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
15. [Moderate dose methotrexate with citrovorum factor rescue therapy in the treatment of head and neck cancer].
Inuyama Y; Hiroto I; Taketa C; Horiuchi M; Mashino S; Fujii M; Matsuura S; Satake B; Takeoda S; Nishijima W; Okuda M; Sakaguchi K; Tanigaito Y; Imakirei M; Konno T; Hirokawa T; Takada K; Ono I; Saitoh H; Takemiya S; Shimada F; Omura K; Miyake H; Fujii K; Kawabe Y; Kondoh T; Komiyama S; Yanagida T; Matsumura Y; Hirano M; Araki S
Gan To Kagaku Ryoho; 1982 Dec; 9(12):2193-200. PubMed ID: 6764099
[TBL] [Abstract][Full Text] [Related]
16. Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children.
Winograd B; Lippens RJ; Oosterbaan MJ; Dirks MJ; Vree TB; van der Kleijn E
Eur J Clin Pharmacol; 1986; 30(2):231-8. PubMed ID: 3709652
[TBL] [Abstract][Full Text] [Related]
17. [High dose methotrexate with CF rescue therapy in patients with head and neck cancer].
Inuyama Y; Taketa C; Hiroto I; Fujii M; Takaoka T; Tanaka J; Matsuura S; Satake B; Takeoda S; Nishijima W
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1823-31. PubMed ID: 6332576
[TBL] [Abstract][Full Text] [Related]
18. Comparison of linear and tapered intravenous infusion of methotrexate in oncochemotherapy. A theoretical approach.
Termond EF; Zonnenberg B; Winograd B; Oosterbaan MJ; Van der Kleijn E; Vree TB
Pharm Weekbl Sci; 1985 Aug; 7(4):158-62. PubMed ID: 4047914
[TBL] [Abstract][Full Text] [Related]
19. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
20. A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer.
Eisenberger M; Krasnow S; Ellenberg S; Silva H; Abrams J; Sinibaldi V; Van Echo D; Aisner J
J Clin Oncol; 1989 Sep; 7(9):1341-5. PubMed ID: 2671289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
